Exosome isolation manufacturing and characterization
New service to reliably and reproducibly isolate exosomes from almost any biofluid.
Amsbi has announced an exosome isolation, manufacturing and characterization service to enable R&D groups to accelerate their discovery and development activities.
Exosomes are small membrane vesicles with a size ranging from 40 to 100 nm. They are known to serve as functional mediators in cell interaction leading to cancer metastasis and have also been implicated in neurodegenerative diseases. Metastasis is a complex multistep process of cancer cell invasion, survival in blood vessels, attachment to and colonization of the host organ. Exosomes influence every step of this cascade and therefore represent a novel strategy for cancer therapy.
Drawing upon many years’ experience of working with exosomes, Amsbio is able to reliably and reproducibly isolate exosomes from almost any biofluid including plasma and tissue culture media, cerebrospinal fluid, synovial fluid, and even challenging fluids such as mouse bronchial alveolar fluid.
The new service enables labs to simply provide Amsbio with a biofluid and in return receive high-quality, functional exosomes that are ready to use. Backed by expert scientific support, the Amsbio exosome isolation and manufacturing service is available across a range of production scales to suit research needs now and development needs in future.
All exosomes supplied by Amsbio come complete with Nanoparticle Tracking Analysis (NTA) characterization data. NTA characterization data provides a clearer picture of the quality of your exosomes without needing to invest in your own NTA instrument. A typical NTA report includes particle analysis data on your exosome including the mean and mode diameter size, particle concentration, and video of the collected data, all gathered in triplicate. This service can also be offered on exosome samples prepared in your own lab.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.